Cargando…

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine

Background: Studies reporting the long-term humoral response after receiving the BNT162b2 COVID-19 vaccine are important to drive future vaccination strategies. Yet, available literature is scarce. Covidiagnostix is a multicenter study designed to assess the antibody response in >1000 healthcare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrari, Davide, Clementi, Nicola, Criscuolo, Elena, Ambrosi, Alessandro, Corea, Francesca, Di Resta, Chiara, Tomaiuolo, Rossella, Mancini, Nicasio, Locatelli, Massimo, Plebani, Mario, Banfi, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620373/ https://www.ncbi.nlm.nih.gov/pubmed/34835288 http://dx.doi.org/10.3390/vaccines9111357

Ejemplares similares

Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine
por: Ferrari, Davide, et al.
Publicado: (2022)

Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects
por: Ferrari, Davide, et al.
Publicado: (2021)

Exploratory assessment of serological tests to determine antibody titer against SARS‐CoV‐2: Appropriateness and limits
por: Colombini, Alessandra, et al.
Publicado: (2022)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

SARS-CoV-2 infection despite high levels of vaccine-induced anti-Receptor-Binding-Domain antibodies: a study on 1110 health-care professionals from a northern Italian university hospital
por: Ferrari, Davide, et al.
Publicado: (2022)

IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients
por: Takazono, Takahiro, et al.
Publicado: (2023)

Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2
por: Criscuolo, Elena, et al.
Publicado: (2022)

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
por: Jo, Dong-Ho, et al.
Publicado: (2021)

Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)

One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine
por: Wand, Ori, et al.
Publicado: (2023)

Six months SARS-CoV-2 serology in a cohort of mRNA vaccinated subjects over 90 years old
por: Tomaiuolo, Rossella, et al.
Publicado: (2022)

Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects
por: Ferrari, Davide, et al.
Publicado: (2021)

Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination
por: Kurashima, Kazuyoshi, et al.
Publicado: (2022)

Influenza B-cells Protective Epitope Characterization: A Passkey for the Rational Design of New Broad-Range Anti-Influenza Vaccines
por: Clementi, Nicola, et al.
Publicado: (2012)

Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults
por: Herzberg, Jonas, et al.
Publicado: (2022)

Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
por: Izumo, Takehiro, et al.
Publicado: (2021)

Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy
por: Castelli, Matteo, et al.
Publicado: (2021)

Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
por: Agur, Timna, et al.
Publicado: (2022)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials
por: Criscuolo, Elena, et al.
Publicado: (2021)

Challenges of the Effectiveness of Traumatic Brain Injuries Biomarkers in the Sports-Related Context
por: Tomaiuolo, Rossella, et al.
Publicado: (2023)

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
por: Israel, Ariel, et al.
Publicado: (2021)

Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection
por: Israel, Ariel, et al.
Publicado: (2021)

Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia
por: Álvarez-Díaz, Diego A., et al.
Publicado: (2022)

Association between γ-Glutamyl Transpeptidase and SARS-CoV-2 Spike Antibody Titers among BNT162b2 Vaccine Recipients
por: Islam, Zobida, et al.
Publicado: (2022)

Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
por: Clementi, Nicola, et al.
Publicado: (2020)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2
por: Bayart, Jean-Louis, et al.
Publicado: (2021)

Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients
por: van Dam, P.A., et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays
por: Padoan, Andrea, et al.
Publicado: (2021)

JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?
por: Diotti, Roberta Antonia, et al.
Publicado: (2013)

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)

Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection
por: Morales-Núñez, José Javier, et al.
Publicado: (2021)

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers
por: Padoan, Andrea, et al.
Publicado: (2021)

1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
por: Debie, Y., et al.
Publicado: (2022)

Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan
por: Matsuura, Tomoka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mtbog3n76358e8bea39vgopijs